{"id":66683,"date":"2016-03-25T03:51:07","date_gmt":"2016-03-25T01:51:07","guid":{"rendered":"http:\/\/www.myza.co.za\/evening-talks-lecture-lucie-bruijn-phd-mba\/"},"modified":"2016-03-25T03:51:07","modified_gmt":"2016-03-25T01:51:07","slug":"evening-talks-lecture-lucie-bruijn-phd-mba","status":"publish","type":"post","link":"https:\/\/www.myza.co.za\/press\/evening-talks-lecture-lucie-bruijn-phd-mba\/","title":{"rendered":"Evening Talks Lecture: Lucie Bruijn, PhD, MBA"},"content":{"rendered":"

Evening Talks Lecture: Lucie Bruijn, PhD, MBA<\/a><\/strong><\/p>\n

A South Africa Event on 2016-06-28 18:30:00<\/i><\/p>\n

Affliation: ALS Association Biography:\u00a0Lucie Bruijn, Ph.D. joined The ALS Association in January 2001 and is currently the Chief Scientist.\u00a0 Prior to that Dr. Bruijn led a team at Bristol Myers Squibb developing in vitro and in vivo model systems for neurodegenerative disease. Realizing the potential of stem cell therapy for neurodegenerative diseases, her team worked with experts in academia to establish stem cell studies at Bristol Myers Squibb. Dr. Bruijn received her Bachelor\u2019s degree in Pharmacy at Rhodes University, South Africa.\u00a0 She received a Master\u2019s degree in Neuroscience and a Ph.D. in Biochemistry, specializing in disease mechanisms of Alzheimer\u2019s disease, at the University of London, United Kingdom. She received her MBA at Imperial College, London, United Kingdom. She joined Dr. Don Cleveland\u2019s laboratory in 1994 where she developed and characterized a mouse model of ALS (mice expressing the familial-linked SOD1 mutation).\u00a0 Using this model her studies focused on disease mechanisms.\u00a0 In addition, in collaboration with Dr. Robert Brown she looked for neurofilament mutations in familial and sporadic ALS patients. At The ALS Association, Dr. Bruijn leads a global ALS research effort,\u00a0Translational\u00a0Research to\u00a0Advance\u00a0Therapies for\u00a0ALS\u00a0(TREAT ALS\u2122) with the goal to move treatment options from \u201cbench to beside.\u201d\u00a0 She has made it a priority to collaborate with other funding agencies, in particular The National Institute of Health, The Department of Defense and many other not-for-profit ALS organizations, as well as other foundations focusing on neurodegenerative research. These collaborations ensure that increased dollars are spent on ALS research. She is involved in project development, encouraging partnerships with academia and biotech, and has played a key role in forging collaborations amongst investigators.\u00a0 It is her strong belief that only through collaboration among a wide range of disciplines will we be successful in changing the course of ALS and finding a cure.\u00a0 Through participation at scientific meetings both nationally and internationally ALSA receives wide-spread recognition amongst the scientific community.\u00a0 Dr. Bruijn represents The ALS Association on several scientific and research committees world-wide and acts as advisor to scientists, government officials and industry leaders seeking council in the field of ALS research. She continues to publish in the field in peer-reviewed journals and remains actively engaged in understanding the most recent research developments. The Evening Talks Series is sponsored by The Pyewacket Fund of the New York Community Trust.<\/p>\n

at WNYC-AM<\/a>
\n160 Varick Street
\nNew York, United States<\/p>\n

Add your South Africa<\/em> event for free here<\/a> on MyZA.<\/p>\n","protected":false},"excerpt":{"rendered":"

Evening Talks Lecture: Lucie Bruijn, PhD, MBA A South Africa Event on 2016-06-28 18:30:00 Affliation: ALS Association Biography:\u00a0Lucie Bruijn, Ph.D. joined The ALS Association in January 2001 and is currently the Chief Scientist.\u00a0 Prior to that Dr. Bruijn led a team at Bristol Myers Squibb developing in vitro and in vivo model systems for neurodegenerative […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","ngg_post_thumbnail":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9840],"tags":[12741,5878,11841,12740,581],"class_list":{"0":"post-66683","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-eventful","7":"tag-bruijn","8":"tag-evening","9":"tag-lecture","10":"tag-lucie","11":"tag-talks","12":"entry"},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.myza.co.za\/press\/wp-json\/wp\/v2\/posts\/66683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.myza.co.za\/press\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.myza.co.za\/press\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.myza.co.za\/press\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.myza.co.za\/press\/wp-json\/wp\/v2\/comments?post=66683"}],"version-history":[{"count":0,"href":"https:\/\/www.myza.co.za\/press\/wp-json\/wp\/v2\/posts\/66683\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.myza.co.za\/press\/wp-json\/wp\/v2\/media?parent=66683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.myza.co.za\/press\/wp-json\/wp\/v2\/categories?post=66683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.myza.co.za\/press\/wp-json\/wp\/v2\/tags?post=66683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}